Patents by Inventor Marcin KOWANETZ

Marcin KOWANETZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220195066
    Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
  • Publication number: 20220152215
    Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Publication number: 20220146517
    Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: August 16, 2021
    Publication date: May 12, 2022
    Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
  • Patent number: 11300570
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: April 12, 2022
    Assignees: Genentech, Inc., Foundation Medicine, Inc.
    Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
  • Patent number: 11299544
    Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: April 12, 2022
    Assignee: Genentech, Inc.
    Inventors: Daniel Shin-Yu Chen, Priti Hegde, Hartmut Koeppen, Marcin Kowanetz
  • Publication number: 20220073623
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from NSCLC to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor cells and/or tumor-infiltrating immune cells).
    Type: Application
    Filed: November 26, 2021
    Publication date: March 10, 2022
    Inventor: Marcin KOWANETZ
  • Patent number: 11254987
    Abstract: This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 22, 2022
    Assignee: GENENTECH, INC.
    Inventors: Edward Kadel, Marcin Kowanetz, Kimberly Walter
  • Publication number: 20210140967
    Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 13, 2021
    Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
  • Publication number: 20200333348
    Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: May 20, 2020
    Publication date: October 22, 2020
    Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
  • Publication number: 20200270348
    Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
    Type: Application
    Filed: May 11, 2020
    Publication date: August 27, 2020
    Inventors: Marcin KOWANETZ, Hartmut KOEPPEN, Zachary BOYD, Zhiming LIAO, Yifei ZHU, Bharathi VENNAPUSA, Patrick C. ROCHE
  • Patent number: 10689445
    Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 23, 2020
    Assignees: Ventana Medical Systems, Inc., Spring BioScience Corporation
    Inventors: Marcin Kowanetz, Hartmut Koeppen, Zachary Boyd, Zhiming Liao, Yifei Zhu, Bharathi Vennapusa, Patrick C. Roche
  • Publication number: 20200157635
    Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).
    Type: Application
    Filed: October 3, 2019
    Publication date: May 21, 2020
    Inventors: Marcin KOWANETZ, Mahrukh HUSENI, Wei ZOU
  • Publication number: 20200041520
    Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 6, 2020
    Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
  • Publication number: 20200031936
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.
    Type: Application
    Filed: October 17, 2019
    Publication date: January 30, 2020
    Inventors: Priti HEGDE, Marcin KOWANETZ, Gregg FINE, Sanjeev MARIATHASAN, Richard BOURGON
  • Publication number: 20190219586
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.
    Type: Application
    Filed: April 1, 2019
    Publication date: July 18, 2019
    Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
  • Publication number: 20190195882
    Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 27, 2019
    Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
  • Publication number: 20180363066
    Abstract: Methods of evaluating tumor mutational burden in a sample, e.g., a tumor sample or a sample derived from a tumor, from a subject, are disclosed.
    Type: Application
    Filed: August 28, 2018
    Publication date: December 20, 2018
    Inventors: Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Garrett Michael Frampton, Priti Hegde, Marcin Kowanetz, Philip J. Stephens, James Xin Sun, Roman Yelensky
  • Publication number: 20180313845
    Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 1, 2018
    Inventors: Marcin KOWANETZ, Daniel Shin-Yu CHEN, Hartmut KOEPPEN
  • Publication number: 20180216196
    Abstract: This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.
    Type: Application
    Filed: November 22, 2017
    Publication date: August 2, 2018
    Applicant: Genentech, Inc.
    Inventors: Edward KADEL, Marcin KOWANETZ, Kimberly WALTER
  • Publication number: 20180037655
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.
    Type: Application
    Filed: October 23, 2017
    Publication date: February 8, 2018
    Inventors: Priti HEGDE, Marcin KOWANETZ, Gregg FINE, Sanjeev MARIATHASAN, Richard BOURGON